EZH2 inhibitor tazemetostat in patients with relapsed or refractory,BAP1-inactivated malignant pleural mesothelioma: a multicentre,open-label,phase 2 study |
| |
| Institution: | 1. Memorial Sloan Kettering Cancer Center, New York, NY, USA;2. Barts Cancer Institute, Queen Mary University of London and St Bartholomew''s Hospital, London, UK;3. Institut Bergonie, Bordeaux, France;4. Royal Marsden Hospital, The Institute of Cancer Research, London, UK;5. Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK;6. Institut Gustave Roussy, Villejuif, France;7. Hospital of the University (CHU) de Lille, Lille, France;8. City of Hope National Medical Center, Duarte, CA, USA;9. UCL Cancer Institute and University College London Hospitals, London, UK;10. Department of Thoracic Surgery, University of California, Los Angeles, CA, USA;11. Mayo Clinic, Rochester, MN, USA;12. Epizyme, Cambridge, MA, USA;13. Leicester Cancer Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK |
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
